As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a rapid pace the last several  years. Considered experimental not too long ago and used primarily in research settings, clinicians across the globe are rapidly coming to accept the utility of proton therapy for numerous indications — a list that many expect to continue to grow rapidly.


Continuing education and training are essential in the healthcare industry. Physicians are required to earn a certain number of continuing medical education credits to maintain license registration, and radiologic technologists must earn a certain number of continuing education credits to maintain American Registry of Radiologic Technologists (ARRT) certification and registration.


Cancer is perhaps the most highly personal, complex disease in our world today. While the various types of cancer are well-established, no two cases are ever the same. Because of this, a multidisciplinary approach is often required, with a healthcare team assembled from across the hospital. Oncology information systems (OIS), also called oncology information management systems (OIMS), are designed to help coordinate care among providers.


University Medical Center Groningen (UMCG) is one of the largest hospitals in the Netherlands. The hospital provides world-class patient care and is engaged in cutting-edge scientific research and medical education. UMCG is a leading cancer center and will soon open a new state-of-the-art proton therapy center. 

The ITN team recently attended the Association for Medical Imaging Management (AHRA)’s 45th Annual Meeting and Exposition in Anaheim, Calif., where nearly 1,000 members, vendors and presenters came together to learn and network. We learned from the three nationally renowned keynote speakers, more than 100 breakout sessions and from the new technology showcased in the exhibit hall by 160 different companies.


Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology and has prompted the implementation of radiation dose monitoring systems. Prior to these systems, dose measurements either were not tracked or required manual calculation of dose based on scanner data in the DICOM headers. 


September 7, 2017 — Sapheneia and Scannerside received U.S. Food and Drug Administration (FDA) 510(k) clearance to market their XR-29 DoseCheck solution.

The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory Committee (MIDAC) on Sept. 8 to discuss regulatory approaches for use of gadolinium-based contrast agents (GBCAs).

Subscribe Now